Scilex Holding Company (US:SCLX) — Company Overview, News & Financial Data
Scilex Holding Company develops non-opioid pain management solutions aimed at improving quality of life for pain sufferers.
Scilex Holding Company
Scilex (NASDAQ:SCLX) focuses on developing and bringing to market non-opioid pain management solutions aimed at substantially improving the quality of life for those suffering from pain. With a keen emphasis on innovation and patient safety, Scilex is committed to redefining pain management through its pipeline of products and projects. The company's approach centers on leveraging cutting-edge science and technology to create therapies that can address the needs of the millions of people worldwide who seek effective pain relief without the risk of opioid addiction. Scilex's objectives are firmly rooted in the advancement of novel, safer treatment alternatives that promise both efficacy and accessibility for patients in need.
Snapshot
Operations
Products and/or services of Scilex Holding Company
- ZTlido (lidocaine topical system) 1.8% is a non-opioid patch for pain relief from postherpetic neuralgia.
- SP-102 (Semdexa), a non-opioid injection, targets lumbar radicular pain (sciatica), awaiting FDA approval.
- Elyxyb, an orally administered, prescription solution for acute migraine treatment in adults.
- SP-103, a lidocaine-based non-opioid topical system, is in development for chronic low back pain.
- SP-104, 4% hydrogel, an extended-release, non-opioid local anesthetic formulated for post-surgical pain.
- Gloperba, an oral solution for prophylaxis of gout flares in adults, offering dosing flexibility and ease of use.
Scilex Holding Company executive team
- Dr. Henry H. Ji Ph.D.CEO, President & Executive Chairman
- Mr. Stephen MaSenior VP, CFO, COO, Corporate Secretary & Director
- Dr. Suketu D. Desai Ph.D.Interim Chief Technical Officer & Senior VP
- Ms. Gigi DeGuzmanVP & Chief People Officer
- Mr. Suresh K. KhemaniSenior VP, Chief Commercial Officer & GM of Scilex Pharma
- Dr. Dmitri V. Lissin M.D.Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer